Rachel Shenker

Dr. Rachel Shenker

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2017 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
RSRachel Shenker
Rachel Shenker
EMEmory R. McTyre
Emory R. McTyre
JRJimmy Ruiz
Jimmy Ruiz
KWKathryn E. Weaver
Kathryn E. Weaver
CCChristina Cramer
Christina Cramer
MCMichael D. Chan
Michael D. Chan
There is limited data on the effects of smoking on lung cancer patients with brain metastases. This single institution retrospective study of patients with brain metastases from lung cancer who received stereotactic radiosurgery assessed whether smoking history is associated with overall survival, local control, rate of new brain metastases (brain metastasis velocity), and likelihood of neurologic death after brain metastases. Patients were stratified by adenocarcinoma versus nonadenocarcinoma histologies. Kaplan–Meier analysis was performed for survival endpoints. Competing risk analysis was performed for neurologic death analysis to account for risk of nonneurologic death. Separate linear regression and multivariate analyses were performed to estimate the brain metastasis velocity. Of 366 patients included in the analysis, the median age was 63, 54% were male and, 60% were diagnosed with adenocarcinoma. Current smoking was reported by 37% and 91% had a smoking history. Current smoking status and pack‐year history of smoking had no effect on overall survival. There was a trend for an increased risk of neurologic death in nonadenocarcinoma patients who continued to smoke (14%, 35%, and 46% at 6/12/24 months) compared with patients who did not smoke (12%, 23%, and 30%, P = 0.053). Cumulative pack years smoking was associated with an increase in neurologic death for nonadenocarcinoma patients (HR = 1.01, CI: 1.00–1.02, P = 0.046). Increased pack‐year history increased brain metastasis velocity in multivariate analysis for overall patients (P = 0.026). Current smokers with nonadenocarcinoma lung cancers had a trend toward greater neurologic death than nonsmokers. Cumulative pack years smoking is associated with a greater brain metastasis velocity.

31 December 2022 in Advances in Radiation Oncology
Verified
Journal Article
Open access
RSRachel Shenker
Rachel Shenker
TJTimothy L. Johnson
Timothy L. Johnson
MRMarcio Ribeiro
Marcio Ribeiro
ARAnna Rodrigues
Anna Rodrigues
JCJunzo Chino
Junzo Chino
Climate change is one of the direst health threats that humanity faces. We aim to estimate the carbon dioxide (CO2) emissions associated with the energy usage from linear accelerator (LINAC)-based external beam radiation therapy (EBRT) for the most common cancer diagnoses. We identified patients with the 4 most common cancer types treated with curative-intent EBRT. Beam-on time for each fraction was extracted from the treatment planning system and averaged over each site and treatment modality. The power was multiplied by the beam-on time in hours to yield kilowatt hours (kWh). Using the US Environmental Protection Agency Greenhouse Gas Equivalencies calculator, we converted the kWh into estimates of CO2-equivalent emissions for the average US power grid. Idle time of the LINAC was estimated via Varian Medical Systems. A total of 10 patients were included for each of the following modalities: conventionally fractionated for prostate cancer (28 fractions [fx]), prostate stereotactic body radiation therapy (SBRT) (5 fx), 15- and 5-fx regimens for early-stage breast cancer, 3- and 5-fx SBRT regimens for early-stage lung cancer, conventional EBRT (30 fx) for locally advanced lung cancer, and short- (5 fx) and long-course (25-28 fx) for rectal cancer. The modality with the lowest and highest carbon emissions per course, on average, was prostate SBRT (2.18 kg CO2; interquartile range, 1.92-2.30) and conventional treatment for prostate cancer (17.34 kg CO2; interquartile range, 10.26-23.79), respectively. This corresponds to CO2-equivalent emissions of driving an average of 5.4 miles and 41.2 miles in a standard vehicle, respectively. "Standby" mode for a LINAC TrueBeam and Clinac IX uses 112 kWh and 64.8 kWh per day, respectively. We have estimated CO2 emissions arising from direct energy usage of a LINAC for 4 common cancers treated with EBRT. "Standby" mode of a LINAC uses the most energy per day. Comprehensive studies are warranted to minimize the environmental effects of health and cancer care.

24 November 2023 in Oral Oncology
Verified
Journal Article
Closed access
RSRachel Shenker
Rachel Shenker
NRNiema B. Razavian
Niema B. Razavian
RJRalph B. D'AGostino Jr
Ralph B. D'AGostino Jr
YMYvonne M. Mowery
Yvonne M. Mowery
DBDavid M. Brizel
David M. Brizel
RHRyan T Hughes
Ryan T Hughes

22 February 2021 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
RSRachel Shenker
Rachel Shenker
NMNelson H. May
Nelson H. May
JWJoshua D. Waltonen
Joshua D. Waltonen
JYJae Paul Yang
Jae Paul Yang
SOStacey S. O’nEill
Stacey S. O’nEill
RHRyan T. Hughes
Ryan T. Hughes

7 November 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
NANatalie Alphonse-Sullivan
Natalie Alphonse-Sullivan
GTGlen B. Taksler
Glen B. Taksler
TLThomas Lycan
Thomas Lycan
KWKathryn E. Weaver
Kathryn E. Weaver
EMEmory R. McTyre
Emory R. McTyre
JRJimmy Ruiz
Jimmy Ruiz
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Natalie Alphonse-Sullivan1, Glen B. Taksler2, Thomas Lycan3, Kathryn E. Weaver4, Emory R. McTyre1, Rachel F. Shenker5, Brandi R. Page6, Scott Isom7, Adam Johnson1, Michael T. Munley1, Adrian W. Laxton8, Stephen B. Tatter8, Kounosuke Watabe9, Michael D. Chan1 and Jimmy Ruiz3 1Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA 2Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH, USA 3Department of Medicine (Hematology and Oncology), Wake Forest School of Medicine, Winston-Salem, NC, USA 4Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA 5Wake Forest School of Medicine, Winston-Salem, NC, USA 6Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA 7Division of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA 8Department of Neurosurgery, Wake Forest School of Medicine, Winston-Salem, NC, USA 9Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA Correspondence to: Jimmy Ruiz, email: jruiz@wakehealth.edu Keywords: brain metastases; sociodemographics; stereotactic radiosurgery Received: June 19, 2017 Accepted: October 13, 2017 Published: November 07, 2017 ABSTRACT Background: Patient sociodemographic factors such income, race, health insurance coverage, and rural residence impact a variety of outcomes in patients with cancer. The role of brain metastasis at presentation and its subsequent outcomes have not been well characterized in this patient population. Results: Multivariate analysis revealed that median income lower than $50,000 was associated with higher presenting symptom grade for brain metastasis (mean RTOG grade 1.2 vs 1.0, SE = 0.1, p = 0.04) and higher chronic symptom grade (mean RTOG grade 1.3 vs 0.9, SE = 0.1, p = 0.002). Higher area-level median income was associated with a lower symptom grade at diagnosis of brain metastasis (p = 0.0008) and likelihood of hospitalization (p = 0.004). Other sociodemographic factors were not significantly associated with survival, neurologic death, or patterns of failure after stereotactic radiosurgery for brain metastases. Conclusions: Lower median income was associated with a greater symptom burden at the time of diagnosis and need for hospitalization for patients with brain metastases, suggesting a delayed time to presentation. These differences in symptom burden persisted during treatment. Methods: Between January 2000 and December 2013, we identified 737 patients treated with stereotactic radiosurgery for brain metastases. They were characterized by 4 sociodemographic factors: median income, race, rural-urban residence, and health insurance status. Clinical outcomes included stage at diagnosis, symptom grade at presentation, likelihood of hospitalization from brain metastasis, overall survival, local failure, distant brain failure, and neurologic death. Multivariate cox proportional hazards model for each outcome was performed controlling for age, sex, number of brain metastases, and dose to brain metastases.

1 January 2019 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
RSRachel Shenker
Rachel Shenker
EMEmory R. McTyre
Emory R. McTyre
GTGlen B. Taksler
Glen B. Taksler
RDRalph B. D’aGostino
Ralph B. D’aGostino
CCChristina K. Cramer
Christina K. Cramer
MCMichael D. Chan
Michael D. Chan